Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2015-03-24 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于公司关联方占用上市公司资金情况的专项审核报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审核报告" which translates to a "Special Audit Report" regarding related party funds occupied by the listed company Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes an audit opinion by certified public accountants and detailed financial tables about related party fund occupation for the fiscal year ending December 31, 2014. The document is a standalone audit report focusing on a specific issue (related party fund occupation) and is not a full annual report or interim report. It contains audit procedures, audit opinions, and financial data specific to the audit scope. The document length is 2878 characters, which is relatively short but contains substantive audit content rather than just an announcement or certification. Therefore, it fits best under the category of Audit Report / Information (AR). FY 2014
2015-03-24 Chinese
关于召开2014年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2014 Annual General Meeting (AGM) of Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes information about the meeting time, location, agenda items, voting procedures, and proxy forms. The document does not contain financial statements or results but rather the announcement and procedural details for the AGM. The presence of agenda items such as the 2014 annual report to be reviewed at the meeting confirms it is an AGM notice. The document length is about 6755 characters, which is consistent with a detailed meeting notice rather than a full annual report or other filings. Therefore, the document fits the category of AGM Information (AGM-R).
2015-03-24 Chinese
关于吸收合并全资子公司的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the absorption merger of a wholly-owned subsidiary by the parent company. It details the merger transaction, board resolutions, approvals needed, and the impact of the merger. It is not a full financial report, audit report, or earnings release. It is a formal announcement of a corporate action related to restructuring and consolidation of subsidiaries. The document length is 4074 characters, which is relatively short and consistent with an announcement rather than a full report. The content focuses on merger details and approvals rather than financial statements or management discussion. Therefore, the document fits best into the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about a corporate restructuring event that does not fall into more specific categories like M&A filings or merger proxy statements.
2015-03-24 Chinese
内部控制规则落实自查表
Regulatory Filings Classification · 95% confidence The document is titled as an "内部控制规则落实自查表" which translates to "Internal Control Rules Implementation Self-Inspection Form". It contains detailed internal control checklists related to audit committee operations, information disclosure, insider trading controls, fundraising controls, related party transactions, external guarantees, major investments, and other important matters. The document is a self-assessment or internal control checklist rather than a full financial report or audit report. It does not contain financial statements or comprehensive financial data. It is also not an announcement or a brief summary but a detailed internal control compliance document. This type of document fits best under Regulatory Filings (RNS) as it is a compliance-related internal control report that does not fit into other specific categories like Annual Report, Audit Report, or Management Reports. The document length is 4217 characters, which is relatively short but contains substantive internal control information, not just a notice or announcement. Therefore, the best classification is Regulatory Filings (RNS).
2015-03-24 Chinese
第三届监事会第六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the sixth meeting of the third Supervisory Board of Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes approvals of the 2014 Supervisory Board Work Report, the 2014 Annual Report and its summary, the 2014 profit distribution plan, a special report on the use of raised funds, an internal control self-evaluation report, and other corporate governance matters. The document repeatedly states that these reports and proposals will be submitted to the 2014 Annual General Meeting for approval and provides links to the full reports on external websites. The document itself does not contain the full annual report or financial statements but rather the meeting resolutions and summaries. The length is 4047 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an official announcement of meeting resolutions and references to reports rather than the reports themselves.
2015-03-24 Chinese
第三届董事会第七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the Shenzhen Xinlitai Pharmaceutical Co., Ltd. third board of directors' seventh meeting held on March 24, 2015. It includes approvals of the 2014 annual general manager's work report, 2014 board work report, 2014 annual report and its summary, 2014 profit distribution plan, appointment of the 2015 audit firm, use of raised funds, internal control self-assessment report, credit line application, surplus fund usage, absorption merger of a wholly-owned subsidiary, nomination of an independent director candidate, amendments to the company articles of association and shareholders' meeting rules, and the proposal to convene the 2014 annual shareholders meeting. The document also contains independent directors' opinions and references to detailed reports published elsewhere (e.g., the 2014 annual report, independent directors' reports, and other filings on the cninfo website). The document is a board meeting resolution announcement, not the full annual report itself, nor a proxy statement or voting results announcement. It contains no full financial statements but references them. The document is lengthy (9079 characters) and contains substantive content about board decisions and management reports. This fits best under Board/Management Information (MANG) as it announces board meeting resolutions including management reports and governance matters. It is not a full Annual Report (10-K) or Interim Report (IR), nor a Regulatory Filing (RNS) or Report Publication Announcement (RPA) since it contains detailed board resolutions and management decisions rather than just a notice or certification. Therefore, the classification is MANG with high confidence.
2015-03-24 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.